A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome

Recently, results from clinical studies of endoscopic resection of gastrointestinal stromal tumor (GIST) in the stomach are being reported. This procedure has several advantages, such as the provision of a definite diagnosis and therapeutic plan, avoidance of frequent follow-up examination, and reduction of patients’ anxiety. However, several concerns also exist such as a limited number of studies, low R0 resection rate, and relatively shorter follow-up period compared with surgical resection. Nevertheless, it is encouraging that most of the post-procedural complications have been treated with conservative management and that some of the patients did not show recurrence of the tumor during long-term follow-up. The selection of suitable cases and the experience of the endoscopists are the most important factors for successful endoscopic resection of gastric GIST. Development of novel procedures as well as collaboration with laparoscopic surgeons are currently in progress.

Download Full-text

Faculty Opinions recommendation of Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1105194.561388 ◽

2008 ◽

Author(s):

Michael Deininger ◽

Paul La Rosée

Keyword(s):

Chronic Myeloid Leukemia ◽

Imatinib Mesylate ◽

Interferon Alpha ◽

Myeloid Leukemia ◽

Chronic Phase ◽

Long Term Follow Up ◽

Interferon Alpha Treatment

Download Full-text

Frantz's tumor (solid and cystic tumor of the pancreas) with liver metastasis: Successful treatment and long-term follow-up

Journal of Pediatric Surgery ◽

10.1016/0022-3468(95)90701-7 ◽

1995 ◽

Vol 30 (5) ◽

pp. 724-726 ◽

Cited By ~ 62

Author(s):

Minoru Horisawa ◽

Noriji Nijnomi ◽

Taichiro Sato ◽

Syunpei Yokoi ◽

Koji Oda ◽

...

Keyword(s):

Liver Metastasis ◽

Successful Treatment ◽

Cystic Tumor ◽

Long Term Follow Up ◽

Solid And Cystic Tumor

Download Full-text

Long-Term Follow-up Results Over 7 Years for Survival, and Safety with Imatinib Mesylate Accompany with Allogeneic Transplantation for Chronic Myeloid Leukemia

Blood ◽

10.1182/blood.v120.21.4529.4529 ◽

2012 ◽

Vol 120 (21) ◽

pp. 4529-4529

Author(s):

Jun Wang ◽

Aining Sun ◽

Wu Depei ◽

Huiying Qiu ◽

XiaoWen Tang

Keyword(s):

Chronic Myeloid Leukemia ◽

Imatinib Mesylate ◽

Myeloid Leukemia ◽

Conflicts Of Interest ◽

Allogeneic Transplantation ◽

Cytogenetic Response ◽

Hematopoietic Stem ◽

Long Term Follow Up

Abstract Abstract 4529 Objective: To observe the efficacy and safety of imatinib mesylate (IM) accompany with allogeneic transplantation for chronic myeloid leukemia (CML). Methods: During the period from January 2003 to August 2011,we retrospectively observed 95 patients with CML receiving IM for a minimum of 4 months before allogeneic hematopoietic stem cell transplantation (HSCT). Patients with advanced CML received IM from 3 month after transplantation for 12 months. Results: Among 95 enrolled patients (CML-CP 76, CML-AP 10, CML-BP 9), types of transplantation: sib-matched HSCT 64, unrelated-HSCT 19, haplo-HSCT 12. For the whole patients, 7 year overall survival (OS) is 80.5%, and disease free survival (DFS) is 74.5%. Complete hematologic response (CHR) is 93.6%, complete cytogenetic response (CCR) is 84.5%, major cytogenetic response (MCR) is 60.3% at 7 year. For CML-CP1, OS is 83.2% and CML-AP/BC is 33.3% (P<0.05). Compared patients of advanced CML achieving CP2 after IM and with no CP2,the former has better results of CCR or MCR, OS and PFS (P<0.05). The total treatment related mortality (TRM) is 16.8%. Cox multivariate regression analysis of prognostic factors indicates that status of CML and severe acute graft-versus-host disease (aGVHD III-‡W) retain independent predictive value. No increase in rates of serious adverse events was observed with continuous use of IM for up to 7 years. Conclusions: For chronic myeloid leukemia, combining with imatinib mesylate and allogeneic transplantation is a good strategy, with favorable long-term follow-up results and acceptable TRM, especially for the patients with advanced CML. Disclosures: No relevant conflicts of interest to declare.

Download Full-text